Cabaletta Bio’s investigational CD19 CAR T therapy, rese-cel (resecabtagene autoleucel), was manufactured on Cellares’ automated Cell Shuttle system and infused into the first two patients. Cellares reported that the manufacturing run met all release criteria and demonstrated an automated, GMP-compliant approach designed to improve scalability and reduce cost of goods for autologous CAR T. The milestone frames Cell Shuttle as a manufacturing platform that could support flexible, higher-capacity supply while minimizing capital intensity versus manual production models. Cellares positioned the dosing of rese-cel as an early proof point for automated supply chains that can support many patients per year. From a program perspective, rese-cel is engineered for autoimmune indications with a single weight-based infusion strategy to transiently and deeply deplete CD19-positive cells. Early clinical feasibility now shifts toward demonstrating operational reliability across additional batches and patients. For the field, the announcement is another data point in the race to industrialize autologous CAR-T manufacturing, where speed, consistency, and operational scalability remain major bottlenecks to broader patient access.